Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
Want to see ARTV full AI Analyst Report?
ARTV Stock Chart & Stats
$12.55
$0.32(3.02%)
At close: 4:00 PM EST
$12.55
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$1.47 - $14.53
Previous CloseN/A
Volume23.16K
Average Volume (3M)263.36K
Market Cap
$265.70M
Enterprise Value$210.15M
Total Cash (Recent Filing)$108.01M
Total Debt (Recent Filing)$10.94M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
May 07, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding24,716,673
10 Day Avg. Volume430,803
30 Day Avg. Volume263,357
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-158.25
Enterprise Value/Ebitda-2.44
Forecast
1Y Price Target
$17.00Price Target Upside35.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesAnalyst highlights that clinical ACR50 efficacy readouts in refractory rheumatoid arthritis are on track and could provide pivotal evidence of therapeutic benefit if confirmed with adequate follow-up.
Manufacturing And AccessAnalyst notes that allogeneic, non-engineered AlloNK cells offer off-the-shelf availability and lower manufacturing complexity, which may reduce treatment costs and facilitate wider adoption.
Safety And AdministrationAnalyst emphasizes that a benign safety profile with no major cell-therapy toxicities supports potential outpatient administration and use in community treatment centers, which could broaden patient access.
Bears Say
Limited Early DataAnalyst cautions that initial efficacy signals come from a small cohort of about fifteen refractory patients, making conclusions preliminary and dependent on confirmatory studies and longer follow-up.
Trial Design And CostsAnalyst warns that a pivotal rheumatoid arthritis study may require substantially larger patient numbers and a randomized control arm, increasing trial complexity, duration, and development costs.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $14.53 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $265.70M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 8 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Mar 10, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.844 by -$0.006.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,716,673 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.844. Following the earnings report the stock price went up 17.27%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (35.46% Upside)
$17.00 (35.46% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
460.26%
12-Months-Change
Fundamentals
Return on Equity
-60.22%
Trailing 12-Months
Asset Growth
-35.79%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$17.00
▲(35.46% Upside)
Technical Analysis
Ownership Overview
14.80% Insiders
2.18% Mutual Funds
0.09% Other Institutional Investors
81.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---